Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and Bacillus Calmette-Guerin - Preliminary report

Memorias do Instituto Oswaldo Cruz

Volumn 99, Issue 1, 2004, Pages 57-62

  Convit, Jacinto ^a   Ulrich, Marian ^a   Polegre, María Argelia ^a   Avila, Angela ^a   Rodríguez, Noris ^a   Mazzedo, Maria Ilina ^a   Blanco, Belkis ^a  

^a INSTITUTO DE BIOMEDICINA   (Venezuela)

Author keywords

Diffuse cutaneous leishmaniasis; Immunotherapy; Mucocutaneous leishmaniasis

Indexed keywords

ANTIPROTOZOAL AGENT; BCG VACCINE; LEISHMANIA VACCINE;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG FORMULATION; DRUG INDICATION; FEMALE; HUMAN; IMMUNOPHARMACOLOGY; IMMUNOTHERAPY; INJECTION PAIN; INJECTION SITE; LEISHMANIA BRAZILIENSIS; MALE; MEDIATOR; PROMASTIGOTE; SKIN LEISHMANIASIS; VACCINATION; VACCINATION REACTION; VENEZUELA;

LEISHMANIA BRAZILIENSIS; MYCOBACTERIUM BOVIS BCG;

EID: 1642526577     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02762004000100010     Document Type: Article

References (26)

1. Bacellar O, Lessa H, Schiefer A, Machado P, Ribeiro de Jesus A, Dutra WO, Gollob KJ, Carvalho EM 2002. Up-regulation of Th-1 responses in mucosal leishmaniasis patients. Infect Immun 70: 6734-6740.
2. Badaró R, Lobo I, Nakatani M, Muinos A, Netto EM, Coler RN, Reed SG 2001. Successful use of a defined antigen/ GM-CSF adjuvant vaccine to treat mucosal leishmaniasis refractory to antimony: a case report. Braz J Infect Dis 5: 223-232.
3. Barral A, Costa JM, Bittencourt AL, Barral-Netto M, Carvalho EM 1995 Polar and subpolar diffuse cutaneous leishmaniasis in Brazil: clinical and immunopathologic aspects. Int J Dermatol 34: 474-479.
4. Becker I, Volkow P, Velasco-Castrejon O, Salaiza-Suazo N, Berzunza-Cruz M, Domínguez JS, Morales-Vargas A, Ruiz-Remigio A, Pérez-Montfort R 1999. The efficacy of pentamidine combined with allopurinol and immunotherapy for the treatment of patients with diffuse cutaneous leishmaniasis. Parasitol Res 85: 165-170.
5. Bomfim G, Nascimento C, Costa J, Carvalho EM, Barral-Netto M, Barral A 1996. Variation of cytokine patterns related to therapeutic response in diffuse cutaneous leishmaniasis. Exp Parasitol 84: 188-194.
6. Cabrera M, Blackwell JM, Castes M, Trujillo D, Convit J, Shaw MA 2000. Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients. Parasite Immunol 22: 73-79.
7. Cáceres-Dittmar, G, Tapia FJ, Sánchez NA, Yamamura M, Uyemura K, Modlin RL, Bloom BR, Convit J 1993. Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction. Clin Exp Immunol 91: 500-505.
8. Carvalho EM, Barrai A, Costa JM, Bittencourt A, Marsden P 1994. Clinical and immunopathological aspects of disseminated cutaneous leishmaniasis. Acta Trop 56: 315-325.
9. Convit J, Castellanos PL, Rondón AJ, Pinardi ME, Ulrich M, Castes M, Bloom B, García L 1987. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. The Lancet Feb 21: 401-404.
10. Convit J, Castellanos PL, Ulrich M, Castés M, Rondón A, Pinardi ME, Rodríguez N, Bloom BR, Formica S, Valecillos L, Bretaña A 1989. Immunotherapy of localized, intermediate and diffuse forms of American cutaneous leishmaniasis. J Infect Dis 160: 104-115.
11. Convit J, Ulrich M, Fernández CT, Tapia FJ, Cáceres- Dittmar G, Castés M, Rondón AJ 1993. The clinical and immunological spectrum of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 87: 444-448.
12. Convit J, Ulrich M, Zerpa O, Borges R, Aranzazu N, Valera M, Villarroel H, Zapata Z, Tomedes I 2003. Immunotherapy of American cutaneous leishmaniasis in Venezuela, 1990 to 1999. Trans R Soc Trop Med Hyg in press.
13. Díaz NL, Zerpa O, Ponce LV, Convit J, Rondón AJ, Tapia FJ 2002. Intermediate or chronic cutaneous leishmaniasis: leukocyte immunophenotypes and cytokine characterization of the lesion. Exp Dermatol 11: 34-41.
14. Grimaldi Jr G, Tesh RB, McMahon-Pratt D 1989. A review of the geographic distribution and epidemiology of leishmaniasis in the New World. Am J Trop Med Hyg 41: 687-725.
15. Khalil EA, Elhassan AM, Zilstra EE, Osman OF, Eljack IA, Ibrahim ME, Mukhtar MM, Ghalib HW, Modabber F 2000. Safety and immunogenicity of an autoclaved Leishmania major vaccine. East Africa Med J 77: 468-470.
16. Laemmli UK 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature Aug 15, 227(259): 680-685.
17. Lee SI, Heiner DC, Wara D 1986. Development of serum IgG subclass levels in children. Monogr Allergy 19: 108.
18. Lessa HA, Machado P, Lima F, Cruz AA, Bacellar O, Guerreira J, Carvalho EM 2001. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg 65: 87-89.
19. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL 1986. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136: 2348-2357.
20. Pirmez C, Yamamura M, Uyemura K, Paes-Oliveira M, Conceição- Silva F, Modlin R 1993. Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest 91: 1390-1395.
21. Reiner SL, Locksley RM 1993. Cytokines in the differentiation of Th1/Th2 CD4+ subsets in leishmaniasis. J Cell Biochem 53: 323-328.
22. Rodriguez N, De Lima H, Aguilar CM, Rodríguez A, Barker DC, Convit J 2002. Molecular epidemiology of cutaneous leishmaniasis in Venezuela. Trans R Soc Trop Med Hyg 96 (Suppl. 1):S105-S109.
23. Salaiza-Suazo N, Volkow P, Tamayo R, Moll H, Gillitzer R, Pérez-Torres A, Pérez-Montfort R, Domínguez JD, Velasco-Castrejon O, Crippa M, Becker I 1999. Treatment of two patients with diffuse cutaneous leishmaniasis caused by Leishmania mexicana modifies the immunohistological profile but not the disease outcome. Trop Med Int Hlth 4: 801-811.
24. Tokunga T, Yamamoto T, Yamamoto S 1999. How BCG led to the discovery of immunostimulatory DNA. Jap J Infect Dis 52: 1-11.
25. Ulrich M, Rodríguez V, Centeno M, Convit J 1995. Differing antibody IgG isotypes in the polar forms of leprosy and cutaneous leishmaniasis characterized by antigen-specific T cell anergy. Clin Exp Immunol 100: 54-58.
26. Velez ID, del Pilar Agudelo S, Arbelaez MP, Gilchrist K, Robledo SM, Puerta JA, Zicker F, Berman J, Modabber 2000. Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: A randomized controlled trial. Trans R Soc Trop Med Hyg 94: 698-703.